重组人血管内皮抑制素联合胸腔内化疗治疗难治性恶性胸腔积液的临床观察被引量：5

Clinical observation on recombinant human endostatin plus intrapleural chemotherapy in the treatment of refractory malignant pleural effusion

原文传递

导出

摘要目的:观察重组人血管内皮抑制素联合胸腔内化疗治疗难治性恶性胸腔积液的疗效和安全性。方法:27例胸腔内化疗后失败的恶性胸腔积液患者,接受重组人血管内皮抑制素30 mg联合化疗药物胸腔内注射,每周2次,共2～3周,评价治疗结束4周疗效、KPS评分变化和不良反应。结果:11例患者治疗后病情控制良好,有效率为40.7%,15例患者KPS评分改善(55.6%)。疗效达完全缓解和部分缓解患者的KPS评分改善率明显高于疗效为疾病稳定和疾病进展患者(37.0%比18.5%,P=0.03)。不良反应少见,且与重组人血管内皮抑制素无关,未观察到3～4级不良反应。结论:重组人血管内皮抑制素联合化疗治疗难治性恶性胸腔积液的疗效肯定,安全性良好。 OBJECTIVE To evaluate the efficacy and safety of recombinant human endostatin plus mtrapleurat cnemomerapy in the treatment of refractory malignant pleural effusion. METHODS A total of 27 patients with uncontrolled malignant pleural eflusion after intrapleural chemotherapy received treatment with combinant human endostatin plus intrapleural chemotherapy 2 times a week for 2- 3 weeks. Response rate,Kamofsky Performance Status （KPS） and adverse events were evaluated at 4 weeks after treatment. RESULTS The pleural effusion of 11 patients achieved good control, and the response rate was 40. 7 %. KPS of 15 patients improved （55.6%）. Rate of KPS improvement in patients achieved complete response and partial response was higher than that in patients with stable disease and progressive disease （37. 0% vs 1 8. 5 %,P = （0. 03）. Adverse events were un- common and not related to recombinant human endostatin. No grade 3-4 adverse event had been observed. CONCLUSION Re- combinant human endostatin plus chemotherapy was effective and well tolerable in treatment of refractory malignant pleural ef fusion.

作者龙国贤吴洁胡广原

机构地区华中科技大学同济医学院附属同济医院肿瘤科武汉市劳动教育管理局育新医院

出处《中国医院药学杂志》 CAS CSCD 北大核心 2013年第21期1799-1801,共3页 Chinese Journal of Hospital Pharmacy

关键词重组人血管内皮抑制素化疗恶性胸腔积液 recombinant human endostatin chemotherapy malignant pleural effusion

分类号 R969 [医药卫生—药理学]

引文网络
相关文献

参考文献17

1Fenton KN,Richardson JD. Diagnosis and management of ma- lignant pleural effusions[J]. Am J Surg, 1995,170 : 69.
2Ishimoto O, Saijo Y, Narumi K, et al. High level of vascular en dothelial growth factor in hemorrhagic pleural effusion of canc- er[J]. Oncology,2002,63(1 ) ..70 -75.
3Ruiz E,Alma n C, Alegre J,et al. Angiogenie factors and an- giogenesis inhibitors in exudative pleural effusions[J]. Lung, 2005,183(3) : 185-195.
4Hamed EA, El Noweihi AM, Mohamed A, et al. Vasoactive mediators (VEGF and TNF-a) in patients with malignant and tuberculous effusions[J]. Respirology, 2004,9 ( 1 ) : 81-86.
5Thickett DR, Armstrong L, Millar AB, et al. Vascular endothe lial growth factor (VEGF) inflammatory and malignant pleural effusions[J]. Thorax, 1999,54: 707-710.
6Grove CS,Lee YC. Vascular endothelial growth factor: the key mediator in pleural effusion formation [J].Curr Opin Pulm Med,2002,8 (4) :294-301.
7Senger DR,Galli SJ, Dvorak AM, et al. Tumor ceils secrete a vascular permeability factor that promotes accumulation of as- cites fluid[J]. Science, 1983,219: 983-985.
8Yano S, Shinohara H, Herbst RS, et al. Production of experi- mental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth fac- tor/vascular permeability factor by human lung cancer cells [J]. Am J Pathol,2000,157 (6) : 1893-1903.
9Ma X, Yao Y, Yuan D, et al. Recombinant human endostatin endostar suppresses angiogenesis and lymphangiogenesis of malignant pleural effusion in mice[J]. PLoS One,2012,7(12): e53449.
10Fang F,Chen P, Wu X, et al. Therapeutic effects of recombi- nant human endostatin adenovirus in a mouse model of malig- nant pleural effusion[J]. J Cancer Res Clin Oncol, 2009, 135 (5):1149 -1157.

二级参考文献30

1杨林,王金万,汤仲明,刘秀文,黄镜,李树婷,董英,张和平,薛岚,储大同,孙燕.重组人血管内皮抑制素Ⅰ期临床研究[J].中国新药杂志,2004,13(6):548-553. 被引量：154
2杨林,王金万,崔成旭,黄镜,张和平,李树亭,孙燕.重组人血管内皮抑制素YH-16联合用药治疗晚期非小细胞肺癌的多中心Ⅱ期临床试验[J].中国新药杂志,2005,14(2):204-207. 被引量：116
3王金万,孙燕,刘永煜,于起涛,张沂平,李凯,朱允中,周清华,侯梅,管忠震,李维廉,庄武,王东林,梁后杰,秦凤展,卢辉山,刘晓晴,孙红,张燕军,王杰军,罗素霞,杨瑞合,涂远荣,王秀问,宋恕平,周静敏,游丽芬,王竞,姚晨.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究[J].中国肺癌杂志,2005,8(4):283-290. 被引量：630
4蔡艳军,郑大勇,罗荣城,陈锦章,李爱民,席箐乐,丁雪梅.Avastin联合顺铂对VEGF高表达的荷卵巢癌裸鼠腹水的抑制作用[J].南方医科大学学报,2007,27(5):647-649. 被引量：9
5Folkman J. Role of angiogenesis in tumor growth and metastasis [J]. Semin Oncol, 2002, 29(6 Suppl 16) : 15 -18.
6Mohammed KA, Nasreen N, Hardwick J, et al. Bacterial induction of pleural mesothelial monolayer barrier dysfunction[ J]. Am J Physiol Lung Cell Mol Physiol,2001,281 ( 1 ) : 119 - 125.
7Garylee YC,Richard WL, Pleural D. Management of malignant pleural effusions [ J ]. Respirology,2004,9 ( 2 ) : 148 - 156.
8Grove CS, Lee YC. Vascular endothelial growth factor: the key mediator in pleural effusion formation[ J]. Curr Opin Pulm Med, 2002,8 (4) : 294 - 301.
9Robert FO, Herbst RS, Colson YL, et al. Clinical cancer advances 2006: major research advances in cancer treatment, p revention, and screening2a report from the american society of clinical oncotogy[ J]. J Clin Oncot,2007,25 ( 1 ) :1 - 17.
10Fang F,Chen P,Wu X,et al.Therapeutic effects of recombihant human endostatin adenovirus in a mouse model of malignant pleural effusion[J].J Cancer Res Clin Oncol,2009,135(5):1149-1157.